Selected Publications by UF Faculty: Pharmacoeconomics and Outcomes Research

Economics of HIV Disease

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG.  Economic efficiency of genetic screening to inform the use of abacavir in the treatment of HIV.  PharmacoEconomics.  2010;28(11):1025-39.

Kauf TL, Roskell N, Shearer A, Gazzard B, Mauskopf J, Davis EA, and Nimsch C.  A predictive model of health state utilities for HIV patients in the modern era of highly-active antiretroviral therapy.  Value in Health.  2008;11(7):1144-53.

Mauskopf J, Kitahata M, Kauf TL, and Tolson J.  HIV antiretroviral treatment:  Early versus later.  J Acquir Immune Defic Syndr. 2005;39(5):562-9.


Economics of HCV Disease and Patient Decision-Making in HCV and other Therapeutic Areas

Grant WC, Kauf TL.  A patient choice model with mid-therapy information. The Patient: Patient-Centered Outcomes Research.  2009;2(3):143-9.

Jhaveri R, Grant W, Kauf TL, and McHutchison J.  The burden of hepatitis C virus infection in children:  Estimated direct medical costs over a 10 year period.  Journal of Pediatrics.  2006;148(3):353-8.

Grant W, Jhaveri R, McHutchison J, Schulman KA, and Kauf TL.  Hepatitis-C healthcare utilization trends in the United States. Hepatology.  2005;42(6):1406-13.

Johnson FR, Özdemir S, Hauber B, and Kauf TL.  Women’s willingness to accept perceived risks for vasomotor symptom relief.  Journal of Women’s Health.  2007;16(7):1028-40.


Other Pharmacoeconomic and Cost Evaluations

Hampp C, Kauf TL, Saidi AS, Winterstein AG.  Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.  Archives of Pediatric & Adolescent Medicine.  2011;165(6):498-505.

Kauf TL.  Methodological concerns with economic evaluations of meningococcal vaccines.  PharmacoEconomics.  2010;28(6):449-61.

Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease.  Am J Hematol. 2009;84(6):323-7.

Hampp C, Hartzema AG, and Kauf TL.  Cost-utility analysis of rimonabant in the treatment of obesity.  Value in Health.  2008;11(3):389–99.

Kauf TL, Velazquez E, Crosslin D, et al.  The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry.   American Heart Journal.  2006;151:206-212.